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Abstract 
Background: We investigated whether variation in the dopamine D2 receptor gene (DRD2) and tri‑dimensional 
personality questionnaire (TPQ) scores could be used to aid adjustment of daily methadone requirements of heroin 
addicts. DRD2 TaqI B polymorphisms and TPQ scores were determined in 138 male Taiwanese heroin addicts who 
were receiving methadone treatment. Borderline index (harm avoidance + novelty seeking—reward dependence) 
was calculated for each subject, and three groups were defined: high (mean from all subjects plus 1 standard devia‑
tion, or greater), low (half of the calculated high score, or lower) and medium (all values between the high and low 
scores).
Results: No significant differences in age (p = 0.60), mean methadone dose (p = 0.75) or borderline index group 
(p = 0.25) were observed between subjects bearing the B1/B1, B1/B2 and B2/B2 DRD2 TaqI genotypes. Among the 
individuals with low (≤10), medium (11–20) and high (≥21) borderline index scores, there was a significant difference 
in mean methadone dose (p = 0.04), but not age (p = 0.90). Further analysis showed that mean methadone dose was 
significantly higher in subjects with low borderline index scores than in those with high scores (62.5 vs. 47.0 mg/day, 
p = 0.03). The odds ratio for a daily methadone requirement ≥60 mg (median dose across the 138 subjects) was 2.64‑
fold greater in the low borderline index group than in the high group (p = 0.04).
Conclusions: Although the DRD2 TaqI B genotype was not associated with methadone use requirements, borderline 
index was revealed as a potential predictive marker for the adjustment of methadone dosage requirements in heroin 
addicts.
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Background
Rates of illicit opioid use are continuing to rise on a global 
scale, with North America being among the regions with 
most problematic levels of opioid use [1–3]. In Taiwan, 
heroin addiction is still a serious problem with approxi-
mately 50–100,000 people dependent on the drug, 
accounting for more than 90 % of all illicit drug users [4]. 
The situation has a dangerous impact on national health. 
This trend highlights the urgent need to focus on preven-
tive measures against HCV and HIV infection caused 
by needle sharing among the heroin-using population. 
In order to reduce the occurrence of these public health 
threats, methadone, the cost-effective replacement for 
heroin dependence, was introduced as a maintenance 
treatment for heroin addiction in Taiwan in 2006 [4]. 
Since then, new HIV cases related to drug use by injec-
tion have declined steadily: 38.54  % in 2007, 35.87  % in 
2008, 34.44 % in 2009, 32.15 % in 2010, 29.85 % in 2011 
and 27.58  % in 2012 [4]. From the viewpoint of infec-
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is worthy of support. However, the quality of metha-
done treatment programs is a concern. Identifying the 
required methadone dose in each individual is crucial to 
successfully blocking the effects of heroin, thus reducing 
drug cravings and preventing relapses and adverse reac-
tions [5].
Genetic factors that determine drug absorption, dis-
tribution, metabolism and action contribute to the large 
inter-individual variability in drug response [6]. Dopa-
mine receptors play a major role in the rewarding effects 
of drugs of abuse [7]. Variations in the dopamine D2 
receptor gene (DRD2) are strongly associated with opiate 
addiction [7]. Polymorphisms of DRD2, located in intron 
2 (TaqI B), are significantly associated with polysubstance 
abuse in white, but not black, Americans [7]. Personality 
traits have been considerable heritable components and 
dopaminergic transmission has been suggested to influ-
ence certain personality traits, among them novelty seek-
ing [8, 9]. The dopamine D2 receptor and its gene (DRD2) 
have also been associated with novelty seeking and 
related traits [10, 11]. Inherited behavioural propensity 
(temperament) is important for identifying substance-
dependent patients and is strongly linked with the risk of 
drug abuse [11–14]. Cloninger has proposed a biosocial 
theoretical model of human personality based on three 
heritable independent dimensions: (1) Novelty Seeking, 
which is the tendency to respond actively to novel stimuli 
leading to pursuit of rewards and escape from punish-
ment; (2) Harm Avoidance, which is the tendency toward 
an inhibitory response to signals of aversive stimuli that 
lead to avoidance of punishment and nonreward; and (3) 
Reward Dependence, which is the tendency for a positive 
response to signals of reward to maintain or resist behav-
ioral extinction [9, 15–17]. Further developments in the 
model have preserved the three dimensions within a 
more comprehensive model of personality [18].
We hypothesised that DRD2 gene variant expression 
and tri-dimensional personality questionnaire scores 
could be used to assist with adjustment of daily metha-
done requirements of heroin addicts. We therefore inves-
tigated, for the first time, DRD2 TaqI B polymorphisms, 
tri-dimensional personality questionnaires (TPQs) and 
methadone dose requirements simultaneously in sub-




We enrolled male Taiwanese heroin-dependent patients, 
aged 20 years or older and receiving methadone replace-
ment therapy at the Chia-Yi Branch of Taichung Veterans 
General Hospital, Taiwan. All participants were unre-
lated, and born and living in Taiwan. Potential subjects 
with a history of HIV infection, severe hepatitis, severe 
structural heart disease or arrhythmias were excluded. 
A total of 138 subjects participated in the study. Written 
informed consent was obtained from each participant 
prior to enrolment, and the study was approved by the 
review board of the Chia-Yi Branch of Taichung Veterans 
General Hospital and the ethics board of the Central Tai-
wan University of Science and Technology.
Methadone was selected by the investigator to meet 
each patient’s requirements, in accordance with national 
guidelines, and was administered once daily. Accord-
ing to the clinical picture and therapy success, the dose 
of methadone was then gradually adapted to reach the 
maximum dose needed by that patient. Furthermore, 
a questionnaire was used to register the patients’ spe-
cific demographic characteristics (e.g., educations, mar-
riage, whether use other substance or not, the manners 
and duration of using heroine, and dosage of heroine). 
Physical symptoms were measured using the opiate with-
drawal scale. Urine screening tests were carried out regu-
larly, but at random time intervals, to detect additional 
consumption. Urine samples of each client were always 
temperature tested. Patients with positive urine toxicol-
ogy results were not enrolled in this study [19]. For all 
138 study subjects, daily methadone doses were recorded 
during the predefined observation period of 15 months. 
The TPQ, a lOO-question self-report instrument, was 
developed to measure these dimensions and sub-dimen-
sions [9, 15]. The TPQ was applied to survey all the 138 
study subjects.
Determination of DRD2 TaqI B polymorphisms
Total genomic DNA was isolated from whole blood 
(2  ml) with EDTA as the anticoagulant, using a blood 
DNA isolation kit (Maxim Biotech Inc., San Francisco, 
CA, USA). DRD2 TaqI B expression was determined 
by PCR-restriction fragment length polymorphism as 
reported previously [20]. In brief, forward (5′-GATAC 
CCACTTCAGGAAGTC-3′) and reverse (5′-GATGT 
GTAGGAATTAGCCAGG-3′) primers were used to 
amplify a 459 bp fragment. The reaction was carried out 
in a DNA thermal cycler (Applied Biosystems, Norwalk, 
CT, USA) as follows: denaturation at 94  °C for 4  min, 
35 cycles of maintenance at 94  °C for 30 s, annealing at 
58 °C for 30 s, and primer extension at 72 °C for 30 s; and 
a final extension step at 72 °C for 5 min. The PCR prod-
ucts were digested with Taq I, and analyzed on 3 % aga-
rose gel (NuSieve 3:1, FMC Bioproduct, Rockland, ME, 
USA) containing ethidium bromide. One (459 bp), three 
(459, 267 and 192  bp) and two (267 and 192  bp) frag-
ments were seen for B1/B1, B1/B2 and B2/B2 genotypes, 
respectively. Subjects were divided into three groups 
according to their DRD2 TaqI B polymorphisms. The 
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Taq1B polymorphism would be referred to by the num-
ber rs1079597 and the alleles referred to as A/G or T/C 
depending on the strand the genotype assay targets [21, 
22].
TPQ and borderline index assessments
The TPQ is a 100-item, self-administered, true/false 
instrument comprising three high-grade dimensions: 
harm avoidance, novelty seeking and reward depend-
ence, each with four subscales. A three factor solution 
was extracted from analysis at the scale level which gives 
support to Cloninger’s model [23]. It is designed to meas-
ure biological component of personality. The assessment 
was conducted by two specialists in the Taiwanese ver-
sion of the method [24, 26]. The Chinese version used in 
our study was developed by Chen et al. [23]. According 
to the normative data for TPQ in Taiwan, we divided our 
sample to eight personality patterns (for example, the 
norm of NS/HA/RD in Taiwan is 13.2/13.8/13.5, a profile 
with a NS/HA/RD of 18/17/10 is coded as ++−) [24]. 
Cloninger’s temperament cube theory assumes that each 
pattern is associated with a personality category [17, 26]. 
In the presented study, the borderline pattern (BP) and 
other patterns (OP) were separated into two groups in 
order to examine our hypothesis. To quantitatively calcu-
late the borderline features into a single value, we applied 
the concept of a ‘‘borderline index’’ (BI) developed from 
Huang et  al. [25]. BI is calculated from NS total +  HA 
total − RD total = BI score, because high NS, high HA, 
low RD is the main feature of borderline personality in 
Cloninger’s temperament cube theory. Borderline index, 
defined as harm avoidance  +  novelty seeking—reward 
dependence, as reported recently in Taiwanese subjects 
[25], was calculated for each subject. The participants 
were then divided into three groups, based on their score; 
high (mean borderline index of the 138 study subjects 
plus 1 standard deviation (SD), or greater), low (half of 
the high score, or lower), and medium (scores between 
these high and low limits).
Statistics
Mean age and mean daily methadone dose were com-
pared across subjects in the three genotype groups, using 
ANOVA. Borderline index distribution across genotypes 
was compared using the Chi square test. ANOVA was 
also used to compare mean age and mean daily metha-
done dose among the three borderline index groups. The 
power analysis was performed to explore the effluence of 
sample size on the results; therefore the study enrolled 
138 participants.
Statistical significance was defined as p < 0.05 and mul-
tiple comparisons were followed by Scheffe’s method for 
ANOVA. If significance was identified between several 
groups, the appropriate model was applied to calculate 
the odds ratio (OR) and 95  % confidence interval (CI) 
of the OR to evaluate risk for certain situations. All data 
were analyzed using SPSS version 18.0 for Windows 
(SPSS Inc., Chicago, IL, USA).
Results
The mean (SD) age and mean daily methadone dose of 
the 138 patients were age 39.3 (7.9) years, education 11.3 
(2.4) years and 56.8 (24.8) mg, respectively (Table 1). All 
the patients were treated at least for 15 months, and only 
heroin use. The harm avoidance, novelty seeking, reward 
dependence and borderline index were [mean (SD)] 15.2 
(6.9), 18.1 (7.2), 20.2 (6.3) and 12.5 (8.2), respectively 
(Table 1). High borderline index was calculated to be 21 
(12.5 + 8.2) and a low index was 10 [(12.5 + 8.2)/2]. Age, 
mean methadone dose and borderline index distribution 
did not differ significantly in subjects bearing B1/B1, B1/
B2 and B2/B2 DRD2 TaqI genotypes (p = 0.60, 0.75 and 
0.25, respectively; Table 2). The frequency of the TaqI-B 
genotypes met criteria for Hardy–Weinberg equilibrium, 
p > 0.50, and are consistent with the frequencies reported 
in previous studies [27]. Across the three borderline 
index groups, a significant effect of mean methadone 
dose (p  =  0.04), but not age (p  =  0.90), was observed 
(Table 3). Further analysis showed that the mean metha-
done dose was significantly higher in subjects with a low 
(≤10) borderline index score than in those with a high 
(≥21) score (62.5 vs. 47.0 mg/day, p = 0.03), but no dif-
ference in mean dose was observed between medium and 
high (p = 0.12), and medium and low (p = 0.12) scoring 
subjects.
Therefore, borderline index score was considered a 
risk factor for daily methadone dose requirement. In 
a further analysis, a methadone dose of 60  mg per day 
(median dose among the 138 subjects) was used as the 
cut-off point and the OR for requiring a daily methadone 
dose ≥60 mg in subjects with high borderline index was 
defined as 1.0. In the borderline index assessment, the 
OR of requiring a methadone dose ≥60 mg/day was 2.64 
Table 1 Age, mean methadone daily requirement, TPQ 
scores and borderline index of the 138 study subjects
Mean (SD) Range
Age, year 39.3 (7.9) 21–57
Mean methadone dose, mg/day 56.8 (24.8) 3–140
Harm avoidance 15.2 (6.9) 0–31
Novelty seeking 18.1 (7.2) 0–34
Reward dependence 20.2 (6.3) 1–34
Borderline index 12.5 (8.2) 0–31
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times higher in subjects with a low score than in those 
with a high score (p = 0.04), whereas the OR (1.50) was 
not significant when medium- and high-scoring subjects 
were compared (p = 0.39) (Table 4).
Discussion
Methadone substitution or maintenance therapy is the 
most cost-effective and widely used treatment for heroin 
dependence. Optimal long-term outcomes require indi-
vidualized dosing owing to large interindividual variabil-
ity in methadone response [28].
The DRD2 gene is located at chromosome 11q22–23 
[29]. Genetic variants altering DRD2 expression or func-
tion modulate the individual risk of opiate addiction, 
leading to the need for methadone substitution therapy 
[30–33]. For the DRD2 gene, the polymorphism of most 
concern is TaqI A [34]. A1(+) allele carriers (A1/A1 and 
A1/A2 genotypes) have fewer brain D2 dopamine recep-
tors than A1(−) allele carriers (A2/A2 genotype) [34]. It is 
thought that the TaqI A polymorphism renders the dopa-
minergic system inefficient and rewards substance abuse 
that increases brain dopamine levels [34]. However, in 
studies of methadone treatment for heroin addiction in 
white populations, the opposite association between the 
TaqI A polymorphism and methadone dose is observed 
[30–33]. TaqI B is found in high linkage disequilibrium 
with TaqI A [35]. We therefore investigated TaqI B poly-
morphisms for the subjects enrolled in the present study.
The TaqI B minor allele is significantly associated with 
40  % fewer DRD2 receptor binding sites [36]. A signifi-
cantly higher prevalence of the TaqI B1 allele is found in 
cocaine-dependent white subjects compared with non-
substance-abusing controls [7]. Smokers homozygous for 
the TaqI B2 allele experience progressive improvement in 
self-reported withdrawal symptoms, whereas those with 
the TaqI-B1 allele show little change [37]. DRD2 TaqI B 
is associated with alcoholism with conduct disorder in 
both white and Taiwanese subjects [38, 39]. However, 
our results revealed that TaqI B, similarly to TaqI A, does 
not play an important role in methadone dosage require-
ments, as reported in one study of white subjects [32]. In 
a recent Taiwanese study, subjects with the DRD2 allele 
coding for −214A>G or 939C>T had a two-fold greater 
chance of requiring a lower methadone dose than non-
carriers of the allele [40]. Recent studies have found a 
functional DRD2 polymorphism, which influences splic-
ing of DRD2 and alters the ratio of short:long DRD2 in 
the brain. This polymorphism has also been associated 
with opioid and cocaine addiction, and is an interesting 
variant that warrants further study [41, 42]. DRD2 is wor-
thy of more comprehensive investigation among the Tai-
wanese population.
TPQ data have been reported in Taiwanese individu-
als carrying certain genetic polymorphisms, adolescents 
(including substance users and those with behavioural 
problems), healthy adults, and adults with alcoholism [24, 
25, 39–57]. Those reports reveal personality–gene and 
personality–behaviour interactions. However, no rela-
tionship between TPQ and methadone pharmacology has 
been established to date. In a study of Yugoslavian opiate 
Table 2 Data among  subjects with  different DRD2 TaqI 
polymorphisms

















Table 3 Data among  subjects with  different borderline 
index
a  Multiple comparisons by Scheffe’s method show F = 1.945, p = 0.12 (a vs. b); 
F = 6.835, p = 0.03 (a vs. c) and F = 2.192, p = 0.12 (b vs. c), respectively
Borderline index Age, year
Mean (SD) [range]
Mean methadone dose, mg/
day Mean (SD) [range]
≦10, N = 56 39.3 (6.8) [21–55] 62.5a (20.8) [15–95]
11–20, N = 55 39.5 (9.4) [26–57] 55.8b (26.6) [3–140]
≧21, N = 27 38.8 (7.2) [27–52] 47.0c (29.4) [5–90]
F 0.072 3.489
p value 0.90 0.04a
Table 4 Odds ratios of methadone daily requirement ≥60 mg in subjects with different borderline index
CI confidence interval
Methadone ≥60 mg/day Methadone <60 mg/day Odds ratio 95 % CI p value
Borderline index
 ≤10 38 18 2.64 1.03–6.78 0.04
 11–20 30 25 1.50 0.59–3.79 0.39
 ≥21 12 15 1.0
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addicts, significantly greater novelty-seeking behaviour 
as well as significant divergences of harm avoidance and 
reward dependence were observed compared with the 
control group [13]. A recent study of Malaysians showed 
that heroin addicts had higher scores for novelty-seeking 
and harm-avoidance personality traits, but lower scores 
for reward dependence when compared with control 
subjects [15]. A recent study in Taiwanese heroin addicts 
reported that harm avoidance and novelty seeking scores 
were significantly higher in patients than in controls [57]. 
Conflicting results in Yugoslavians, Malaysians and the 
Taiwanese may be attributable to ethnic differences. How-
ever, therapeutic methadone dose was not addressed in 
the three previously cited studies [13, 15, 57]. In a recent 
study of heroin-dependent Taiwanese subjects, those 
with borderline personality [borderline index: 22.74 (SD 
4.08), n  =  22] showed greater sympathetic activity and 
less parasympathetic activity after taking methadone 
compared to other personalities [borderline index: 16.70 
(4.36), n  =  22] [25]. In that study, current methadone 
dose (around 38  mg/day) was not significantly different 
between the two groups, and the mean methadone dose 
was not investigated [25]. Therefore, to our knowledge, we 
are the first to study the relationship between mean thera-
peutic methadone dose and borderline score in heroin 
addicts. Our results show that the daily methadone dose is 
significantly higher among subjects with borderline index 
scores ≤10 than in those with scores ≥21. We also dem-
onstrate that individuals with borderline index scores ≤10 
had an approximately 2.6-fold greater chance of requiring 
daily methadone doses ≥60  mg than those with border-
line index scores ≥21. This association between border-
line index score and methadone dose is a novel finding.
The TPQ scores are associated with DRD2 TaqI A poly-
morphisms in healthy American boys [58], Taiwanese 
subjects with anxiety, depression and alcohol depend-
ence [47], methamphetamine-dependent Americans [59], 
Finns [60], Germans [61], Russians and Tatars [62] and 
heroin-dependent Malaysians [15], whereas non-associ-
ation was observed in healthy French and Austrian sub-
jects [63, 64] and in depressed patients in a New Zealand 
population [65]. The contradictory results among white, 
Malaysian and Taiwanese populations could be attribut-
able to ethnic differences. In our study, we found no asso-
ciation between DRD2 TaqI B polymorphisms and TPQ 
scores.
In addition to pharmacogenomics, cofactors such as 
age, pathology and sex are also important determinants 
of interindividual variability in drug efficacy. More infor-
mation about the participants other than age should 
be considered in the future, such as the manners and 
duration of using heroine, and dosage of heroine et  al. 
Maybe there are other factors influencing the dosage of 
methadone. In the present study, all the patients were 
men, and we excluded subjects with a history of HIV 
infection, severe hepatitis, severe structural heart disease 
or arrhythmias. Moreover, our results demonstrate that 
the difference in age between the groups was not signifi-
cant. Therefore, our results have less interference from 
other cofactors than previous studies, leading to a more 
confident conclusion than those based only on pharma-
cogenomic factors. A limitation of this study is that the 
significant p values (0.03–0.04) obtained are only slightly 
smaller than 0.05; this may be attributable to the num-
ber of study subjects is not large enough. In this study, 
the further controlled design for population stratification 
should be considered to avoid confounding the associa-
tion between genotype and the trait of interest.
Furthermore, our study does not investigate the mech-
anism underlying low borderline index scores predicting 
the need for higher methadone doses in heroin-depend-
ent patients, and only TaqI B was determined for DRD2 
in our patients. Further investigation of DRD2 variants in 
our patients is warranted. A more comprehensive study, 
with a larger sample size, investigating relationships 
between polymorphisms at nucleotides −214, 939, TaqI 
A and TaqI B in the DRD2 gene, and TPQ scores, bor-
derline index, sympathetic and parasympathetic activity, 
and methadone dose for treatment of heroin-dependent 
subjects, is ongoing in our laboratory.
Conclusions
In conclusion, methadone use requirements in heroin-
dependent subjects were associated with the border-
line index score, but not with DRD2 TaqI B genotype. 
Although the DRD2 TaqI B genotype was not associated 
with methadone use requirements in this study, border-
line index was revealed as a potential predictive marker 
for the adjustment of methadone dosage requirements in 
heroin addicts.
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